Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

TScan Therapeutics (TCRX) Leases (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Leases for 6 consecutive years, with $57.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 10.28% to $57.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.7 million, a 10.28% decrease, with the full-year FY2025 number at $57.7 million, down 10.28% from a year prior.
  • Leases was $57.7 million for Q4 2025 at TScan Therapeutics, down from $59.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $64.4 million in Q4 2024 to a low of $4.4 million in Q3 2022.
  • A 5-year average of $43.1 million and a median of $59.1 million in 2022 define the central range for Leases.
  • Peak YoY movement for Leases: dropped 25.08% in 2022, then soared 1240.18% in 2023.
  • TScan Therapeutics' Leases stood at $5.5 million in 2021, then surged by 976.34% to $59.1 million in 2022, then increased by 7.43% to $63.5 million in 2023, then grew by 1.36% to $64.4 million in 2024, then decreased by 10.28% to $57.7 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Leases are $57.7 million (Q4 2025), $59.4 million (Q3 2025), and $61.1 million (Q2 2025).